New Delhi, April 8 -- Anthropic, the San Francisco-based maker of the Claude AI model, recently acquired Coefficient Bio, a stealth biotech startup, for $400 million in an all-stock deal.

The deal marks the latest push by AI leaders into drug discovery, a space global pharma giants have been racing to claim. But as foundational AI models muscle into biology, what does this latest move mean for India's $55-billion pharmaceutical industry? Mint explains.

Anthropic purchased Coefficient Bio in an all-stock deal, as reported by The Information last week. The startup was founded eight months ago by Samuel Stanton and Nathan Frey, both of whom worked at Genentech's computational drug discovery unit, Prescient Design. Genentech is, in turn, ow...